DCPH - デシフィラ・ファ―マシュ―ティカルズ (Deciphera Pharmaceuticals Inc.) デシフィラ・ファ―マシュ―ティカルズ

 DCPHのチャート


 DCPHの企業情報

symbol DCPH
会社名 Deciphera Pharmaceuticals Inc (デシフィラ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 デシフェラ・ファーマシューティカルズ(Deciphera Pharmaceuticals Inc.)は臨床段階の製薬会社である。同社はがん患者の生活を改善するための薬物を開発している。同社の薬剤候補には、DCC-2618、DCC-3014およびレバスチニブが含まれる。独自のキナーゼスイッチ制御阻害剤プラットフォームは、キナーゼの活性化を阻害する。DCC-2618はDCC-2618は、消化管間質腫瘍(GIST)、進行性全身性肥満細胞症(ASM)、神経膠芽細胞腫(GBM)およびpan-KITまたはPDGFRアルファによって駆動される他の固形腫瘍の治療用経口投与キナーゼスイッチ制御阻害剤である。DCC-3014は、コロニー刺激因子受容体1(CSF1R)の経口投与された強力かつ高度に選択的な阻害剤である。レバスチニブは、経口的に投与され、TIE2免疫キナーゼの強力で選択的な阻害剤である。レバスチニブは、TIE2のスイッチポケットに強力に結合し、阻害スイッチを安定化させ、活性化スイッチを変位させてTIE2シグナル伝達を遮断する。   デシフィラ・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、がん治療の反応速度を制限する薬剤耐性のメカニズムを研究し、がん患者の生活を改善する新薬の開発に従事する。同社独自のキナ―ゼスイッチ制御阻害プラットフォ―ムによる小分子薬物候補は、多くのがんが転移することを防ぐために開発される。本社所在地はマサチュ―セッツ州ウォルサム。   Deciphera Pharmaceuticals, Inc. operates as a biotechnology company which develops and manufactures kinase inhibitor treatments for cancer by cutting off the ability of tumor cells to thrive and spread. The company designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
本社所在地 500 Totten Pond Road Waltham MA 02451 USA
代表者氏名
代表者役職名
電話番号 +1 781-209-6400
設立年月日 42948
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.deciphera.com
nasdaq_url https://www.nasdaq.com/symbol/dcph
adr_tso
EBITDA EBITDA(百万ドル) -76.68100
終値(lastsale) 30.84
時価総額(marketcap) 1161348078.84
時価総額 時価総額(百万ドル) 1182.06
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 836.92100
当期純利益 当期純利益(百万ドル) -75.07000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Deciphera Pharmaceuticals Inc revenues was not reported. Net loss increased from $18.3M to $43.1M. Higher net loss reflects Research and development increase from $13.8M to $33M (expense) General and administrative increase of 97% to $7.2M (expense) Share-based compensation in Selling Gen increase from $672K to $2.3M (expense).

 DCPHのテクニカル分析


 DCPHのニュース

   Deciphera Prepares To Collect Revenue After First FDA Approval: 'We Are Well-Positioned'  2020/05/29 15:49:25 Benzinga
After 17 years of clinical work, Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) finally has a marketable product. The Food and Drug Administration approved Qinlock as a fourth-line treatment of gastrointestinal stromal tumors earlier this month. The kinase inhibitor will be Deciphera’s first sustainable revenue generator, possibly boasting the $32,000-per-month price tag of peer therapies.Yet Deciphera isn’t yet projecting profitability. “We are not yet focused on a real path to profitability,” CEO Steve Hoerter told Benzinga, adding that the practice is common across the industry. “We’re focused on investing capital in the programs we have and getting those programs to important value inflection points as we generate additional data.” The company has “a number of places to invest,” he said. Deciphera's Lead Candidate Deciphera designs kinase inhibitors with the “potential to result in the ability to overcome resistance to other therapies and prevent downstream resistance mutations,” Hoerter said.
   AmerisourceBergen Selected by Deciphera Pharmaceuticals to Support QINLOCK™  2020/05/26 12:30:00 Business Wire
VALLEY FORGE, Pa.--(BUSINESS WIRE)--AmerisourceBergen, a global healthcare solutions leader, announced today that it has been selected by Deciphera Pharmaceuticals (Deciphera) to support QINLOCK (ripretinib). AmerisourceBergen is providing a unified commercialization approach for QINLOCK which was approved by the U.S. Food and Drug Administration (FDA) on Friday, May 15, 2020. QINLOCK is an orally administered kinase switch control inhibitor approved for the treatment of adult patients with adv
   Deciphera (DCPH) Secures Early FDA Nod for GIST Drug Qinlock  2020/05/18 11:22:00 Zacks Investment Research
The FDA lends a speedy nod to Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumors. The approval comes three months ahead of schedule.
   Is a Surprise Coming for Deciphera (DCPH) This Earnings Season?  2020/05/04 12:45:00 Zacks Investment Research
Deciphera (DCPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Is Deciphera Pharmaceuticals (DCPH) Stock a Solid Choice Right Now?  2020/04/23 13:06:00 Zacks Investment Research
Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Is a Surprise Coming for Deciphera (DCPH) This Earnings Season?  2020/05/04 12:45:00 Zacks Investment Research
Deciphera (DCPH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
   Is Deciphera Pharmaceuticals (DCPH) Stock a Solid Choice Right Now?  2020/04/23 13:06:00 Zacks Investment Research
Deciphera Pharmaceuticals (DCPH) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2019 Earnings Call Transcript | The Motley Fool  2020/03/10 01:00:20 The Motley Fool
DCPH earnings call for the period ending December 31, 2019.
   BRIEF-Deciphera Pharmaceuticals Announces Public Offering Of 3.18 Million Shares Of Common Stock At A Price Of $55 Per Share  2020/02/14 05:35:31 Reuters
Deciphera Pharmaceuticals Inc:
   Deciphera's NDA for GIST Drug Gets Priority Review From FDA  2020/02/13 15:31:00 Zacks Investment Research
The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.
   Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2019 Earnings Call Transcript | The Motley Fool  2020/03/10 01:00:20 The Motley Fool
DCPH earnings call for the period ending December 31, 2019.
   BRIEF-Deciphera Pharmaceuticals Announces Public Offering Of 3.18 Million Shares Of Common Stock At A Price Of $55 Per Share  2020/02/14 05:35:31 Reuters
Deciphera Pharmaceuticals Inc:
   Deciphera's NDA for GIST Drug Gets Priority Review From FDA  2020/02/13 15:31:00 Zacks Investment Research
The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.
   The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data  2020/02/12 14:18:32 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: XLRN ) Agile Therapeutics Inc (NASDAQ: AGRX )( announced securing of loan facility) Allergan plc (NYSE: AGN ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Cue Biopharma Inc (NASDAQ: CUE ) Cytokinetics, Inc. (NASDAQ: CYTK ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Nevro Corp (NYSE: NVRO ) Novartis AG (NYSE: NVS )(announced priority review for its lung cancer drug) Pacira Biosciences Inc (NASDAQ: PCRX ) PAVmed Inc (NASDAQ: PAVM )(PAVmed's EsoGuard Esophageal DNA test was accorded Breakthrough Device designation) Penumbra Inc (NYSE: PEN ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Seattle Genetics, Inc. (NASDAQ: SGEN )(announced positive data readout for ADC in bladder cancer) Syneos Health Inc (NASDAQ: SYNH ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) West Pharmaceutical Services Inc. (NYSE: WST ) Zai Lab Ltd (NASDAQ: ZLAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Feb. 11) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) Brickell Biotech Inc (NASDAQ: BBI ) Endologix, Inc. (NASDAQ: ELGX ) Enzo Biochem, Inc. (NYSE: ENZ )( received New York State approval for its gynecological …
   The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology  2020/02/11 12:23:06 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) )(reacted to better-than-expected results and comments that its deal to be acquired by AbbVie is on track to close by the first quarter) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Aptose Biosciences Inc (NASDAQ: APTO ) Arcutis Biotherapeutics Inc (NASDAQ: ARQT ) Ascendis Pharma A/S (NASDAQ: ASND ) AtriCure Inc. (NASDAQ: ATRC ) ChemoCentryx Inc (NASDAQ: CCXI ) Co-Diagnostics Inc (NASDAQ: CODX )(announced sales of its new coronavirus test ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Fulgent Genetics Inc (NASDAQ: FLGT ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD )(reacted to positive data readout from early-stage study of experimental drug to treat eye disorders) Masimo Corporation (NASDAQ: MASI ) Novartis AG (NYSE: NVS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Principia Biopharma Inc (NASDAQ: PRNB ) PTC Therapeutics, Inc (NASDAQ: PTCT ) Revance Therapeutics Inc (NASDAQ: RVNC ) ResMed Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デシフィラ・ファ―マシュ―ティカルズ DCPH Deciphera Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)